NCT01680588View on ClinicalTrials.gov

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Alzheimer Disease
Interventions
DRUG

[18F]NAV4694

Trial Locations (7)

12208

Neurological Associates of Albany, Albany

46202

Indiana Medical Research, Indianapolis

60007

Alexian Brothers Neurosciences Institute, Elk Grove Village

60612

Rush University Medical Center, Chicago

06510

Molecular NeuroImaging, LLC, New Haven

02115

Brigham & Women's Hospital, Boston

02169

Alzheimer's Disease Center, Quincy Medical Center, Quincy

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY